ythdf3 knockdown (Obio Technology Corp Ltd)
Structured Review
Ythdf3 Knockdown, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf3/knockdown+ythdf3/pm41591631-52-3-8
Average 86 stars, based on 1 article reviews
Images
Related Articles
Knockdown:Article Title: Epitranscriptomic regulation of NVP-BEZ235 resistance in ccRCC via the YTHDF3-SYNM regulatory pathway. Article Snippet: 1 The First Clinical Medical College, Faculty of Medicine, Yangzhou University, Yangzhou 225001, China 2 Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225012, China 3 Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China 4 Department of Urology, Suzhou Ninth People’s Hospital affiliated to Soochow University, Suzhou 215000, China 5 Nanjing Medical University, Nanjing 210029, China Abstract Background NVP-BEZ235 is a dual PI3K/mTOR inhibitor with promising antitumor activity in clear cell renal cell carcinoma (ccRCC).. However, the mechanisms underlying acquired drug resistance remain incompletely defined.. Objective To investigate whether epitranscriptomic regulation—specifically N6-methyladenosine (m6A) modification and its reader YTHDF3—drives reversible, non-genetic resistance to NVP-BEZ235 in ccRCC, and to identify key downstream effector genes. |

